Applications, challenges and prospects of mesenchymal stem cell exosomes in regenerative medicine

Aysa Rezabakhsh1, Emel Sokullu2 and Reza Rahbarghazi3,4*

Abstract
Recent advances in the identification and application of different stem cell types have offered alternative therapeutic approaches for clinicians. The lack of successful engraftment, migration into the injured site, loss of functionality and viability, ethical issues, shortage of donated allogeneic stem cells and the possibility of transmission of infectious are the main challenges associated with direct cell transplantation. The discovery and research on exosomes have led to the rise of hopes for the alleviation of different pathologies in regenerative medicine. EXO are nano-sized extracellular vesicles (40–150 nm) and released by each type. These nanoparticles participate in cell-to-cell communication in a paracrine manner. It is thought that the application of EXO can circumvent several drawbacks related to whole-cell therapies. Because of their appropriate size and stability, EXO are touted as therapeutic bullets transferring signaling factors into the acceptor cells in a paracrine manner. Despite these advantages, technologies associated with EXO isolation and purification are challenging because of heterogeneity in exosomal size and cargo. The lack of standard GMP-grade protocols is the main hurdle that limits the extensive application of EXO in the clinical setting. Here, the authors aimed to inspire a logical and realistic vision about problems associated with EXO application in regenerative medicine.

Keywords: Exosomes, Whole-cell therapy, Disadvantages, Challenging, Regenerative medicine

Background
The discovery of stem cells has paved a way to accelerate tissue regeneration via replacing injured cells in paracrine and juxtacrine manners. Among several stem cell types, MSCs exhibit significant trans-differentiation properties into several lineages after transplantation into the target sites [1]. Due to the ease of extraction, presence in most tissues and differentiation into several lineages, MSCs are top-used cells in regenerative medicine compared to the other stem cell types [2]. These cells can be isolated from bone marrow, umbilical cord blood and adipose tissue. To use MSCs in the clinical setting, it is mandatory to expand freshly isolated MSCs in large scales in vitro. Unfortunately, these features can lead to genetic and morphological alterations likely after several passages [3]. Indeed, obtaining cells with similar and typical characteristics is not completely controllable. The viability of transplant cells, migration into the injured sites and integration with host cells are the main hurdles affecting the efficiency of cell-based therapies [4]. It is noteworthy to mention that a large number of exogenously administered MSCs are eliminated irrespective of immune system reaction due to mechanical stress and lack of supporting niche [4]. As a correlate, these drawbacks have forced the researchers to focus on other aspects of stem cell-based therapies.
In addition to the differentiation capacity, stem cells especially MSCs can release several signaling molecules inside nano-sized vesicles namely Exo, ranging from 40 to 150 nm, to remotely regulate the behavior of acceptor cells Exo are can be found in biofluids containing diverse signaling molecules such as miRNA, mRNA, lipids, DNA and proteins [5]. Several experiments have shown that a wide range of MSCs isolated from different tissues display variable Exo secretion capacity [6]. Molecular investigations showed that over 50% of cargo is common between Exo isolated from various types of MSCs [6]. As mentioned previously, a large amount of cargo in MSC Exo correlates with the regulation of cell growth and antioxidant activity [7]. The procedure of Exo biogenesis is intricate and encompasses several consecutive steps inside the cells. In brief, the phenomenon consists of the generation of the endosomal compartment, namely MVBs, from the trans-Golgi apparatus and the invagination of intraluminal vesicles into the lumen of multivesicular bodies [8]. Exo possess high stability during preparation steps and lyophilization. Recent works exhibit immune tolerability even with repeat administration. Due to the cell-free nature, Exo exhibited a better safety profile in which side effects and toxicity after Exo administration is approximately unlikely [9]. Of note, both xenogeneic and allogenic Exo can be administered without provoking immune system reactivity [10]. Compared to MSCs, systemic injection of Exo leads to proficient delivery to the injured site without affecting structural integrity [11]. Compared to their parent MSCs, the levels of systemically injected Exo from natural barriers are higher. The existence of distinct ligands on the exosomal membrane and ligand-mediated endocytosis makes these particles eligible for delivery purposes [12]. Commensurate with these descriptions, Exo have numerous superiorities over MSCs in the regeneration of injured sites. Here, we aimed to highlight some issues and problems related to Exo isolation, purification and application in in vivo conditions.

**Challenges related to Exo application**

While one might hypothesize that Exo are touted as a consolidated therapeutic approach for many, if not most, diseases, the reality is that the application of Exo is at the primitive steps of development for clinical purposes despite putative advantages (Fig. 1 and Table 1). Up to now, different approaches such as precipitation, ultracentrifugation, ultrafiltration, flushing separation, microfluidic isolation, antibody affinity capture and mass spectrometry have been developed for Exo isolation from biological fluids [6] (Table 2). Noteworthy, these techniques are, indeed, laborious, time-consuming and expensive without established protocols. For example, the existence of natural components such as chylomicrons and lipoproteins can affect the isolation of Exo from biofluids [13]. The lack of typical surface markers and the existence of other extracellular vesicle types such as microvesicles commonly lead to co-isolation and impurity of harvested Exo [14, 15]. In conventional approaches, such as ultracentrifugation, changes in morphology and functionality should not be neglected. Isolation of Exo via the high-speed pelleting method can lead to mechanical damage, exosomal membrane distortion, protein aggregation, lipoprotein contamination and low-rate purity [16]. Low-yield rate and alteration of exosomal cargo are possible in Exo collected via ultracentrifugation [17]. The isolation of Exo via ultracentrifugation can alter the final concentration of specific markers compared to the parent cells. Based on the previously conducted experiments, ultracentrifugal isolation of Exo led to a reduction of calnexin while the levels of CD81 and CD9 remained unchanged [18].

Storage is another critical issue related to Exo application in regenerative medicine. It is suggested that the lack of storage protocols can affect their size and composition. The intensity of these changes is higher at temperatures 4 and −20 °C when compared to lower temperatures such as −80 °C [19]. For instance, levels of CD63 and HSP70 are reduced when Exo are stored at higher temperatures such as 4 °C for 10 days [20]. Of note, the loss of exosomal cargo was higher at room temperature [20]. By increasing the temperature of storage conditions, the Exo population exhibits a more dispersed pattern. Many protocols used phosphate-buffered saline as a storage buffer for Exo for cryopreservation. The addition of some components such as trehalose into phosphate-buffered saline can prohibit Exo swelling [21]. Exosomal aggregation or cryodamage is another issue regarding the maintenance at below temperatures, leading to loss of Exo functionality after administration. The increase of freezing/thawing cycles can contribute to Exo aggregation and subcellular localization after the incubation with target cells [22]. The influence of storage pH has also been identified on Exo uptake by the cells. Exo maintained at pH values of 4 and 10 had better uptake levels rather than that of pH 7 [22]. Further elucidation of underlying mechanisms that lead to appropriate cryopreservation without affecting exosomal integrity and function is highly recommended.

The type of guidelines, methods and supplements used for parent MSC cultivation and donor-specific factors affect Exo profile and batch-to-batch variability [23]. It has been confirmed that the exosomal cargo is directly altered when the host cells are exposed to stressful conditions, leading to the increase of distinct factors and proinflammatory cytokines inside Exo [23]. Molecular identification of isolated Exo has indicated a close correlation between cargo type and levels with passage
number. With an increasing passage number, membrane distribution of exosomal markers such as CD63 is reduced [24]. Cellular aging after long-term cultures and numerous passages can alter Exo production capacity and functionality [25]. Considering an initial seeding density of producing cells has an important impact on the quality and quantity of Exo. For example, seeding at higher densities can lead to insufficient Exo production and contamination with culture medium proteins while the cargo profile is also altered [24]. Commensurate with these descriptions, it is highly recommended to develop standard protocols to ensure the quality of isolated Exo from parent cells cultured on in vitro conditions. Along with the quality of parent cell culture and time of incubation, the medium composition is also responsible for Exo consistency. High-glucose medium supports large-sized Exo production with different protein content versus low glucose medium [26]. Other components used commonly in the culture medium are antibiotics and FBS. Prolonged culture of parent cells in the presence of specific antibiotics such as ciprofloxacin, a mycoplasma inhibitor, can increase a load of DNA on the Exo surface. This feature increases the possibility of Exo attachment to ECM protein such as fibronectin [25]. FBS is the source of exogenous Exo with potential bioactivities that can alter the physiology of culturing cells. To be honest, it is not clear to what extent current protocols are useful in the elimination of Exo from FBS, and therefore, the contamination of parent cell Exo and exogenous Exo should not be neglected. Noteworthy, the culture of cells in FBS-free conditions can induce extensive starvation and alter exosomal content [25].

Sterility is another critical issue in the context of Exo therapy (Fig. 2). Considering the approximately the same size among the different viruses and Exo, it is possible to mention that virions, viral products, toxins and bacteria-associated vesicles can be enriched in the Exo fraction. However, the presence of microbe and
fungi in the Exo fraction is low due to their identical size and elimination following the filtration step (Fig. 2) [27]. It has been shown that Exo biogenesis machinery can be hijacked by specific retroviruses such as HIV-1 and HTLV-1 and these viruses use Exo as natural bio-
carriers to spread inside the body and circumvent the immune system responses [28]. The existence of virus-
related genetics and proteins not only increases the

| Status                  | Study                                                                 | Conditions                                                                 | Source                       | Interventions                                      | Phase |
|------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------------|------------------------------|-----------------------------------------------------|-------|
| Not yet recruiting     | Nebulization of MSC Exo in patients with acute respiratory distress syndrome | Acute respiratory distress syndrome                                         | Allogenic MSCs               | Low/medium/and high doses of MSC Exo                | I and II |
| Completed              | Aerosol inhalation of MSC Exo in healthy volunteers                  | Healthy                                                                    | Allogenic adipose MSCs       | 1X to 8X concentration of Exo                       | I     |
| Recruiting             | Effect of umbilical MSCs Exo on dry eye in patients with cGVHD       | Dry eye                                                                    | Umbilical MSCs               | 10ug exosomal protein/drop                          | I and II |
| Completed              | Inhalation of MSC Exo in severe Coronavirus pneumonia                | Coronavirus                                                                | Allogenic adipose MSCs       | 2.0 x 10⁸ nanovesicles/3 ml                          | I     |
| Recruiting             | Allogenic MSC Exo in patients with acute ischemic stroke             | Cerebrovascular disorders                                                  | Allogenic MSCs               | Exo enriched by miR-124                             | I and II |
| Not yet recruiting     | MSC Exo for multiple organ dysfunction syndromes after surgical repair of acute type A aortic dissection | Multiple organ failure                                                     | Umbilical MSCs               | Intravenous administration of Exo (150 mg)          | Not applicable |
| Recruiting             | MSC Exo nebulization for the treatment of pulmonary infection        | Drug-resistant                                                             | Allogenic adipose MSCs       | 8.0 x 10⁸ nanovesicles/3 ml                          | I and II |
| Active, not recruiting | MSC Exo for macular holes                                             | Macular holes                                                              | Umbilical MSCs               | Intravitreal injection of 20–50 μg/10 μl PBS       | I     |
| Not yet recruiting     | MSC Exo for the treatment of acute respiratory distress syndrome (COVID-19) | COVID-19                                                                   | Perinatal MSC Exo            | Intravenous administration of MSC Exo              | I and II |
| Not yet recruiting     | MSC Exo on the therapy for intensively ill children                  | Sepsis and critical illness                                                | MSC Exo                      | ND                                                  | ND    |
| Recruiting             | MSC Exo in patients with Alzheimer’s disease                           | Alzheimer Disease                                                         | Allogenic adipose MSCs       | The nasal drip of low/medium and high doses of MSC Exo | I and II |
| Unknown                | MSC Exo for induction of beta-cell mass in type 1 diabetes mellitus   | Diabetes mellitus type 1                                                  | Cord blood MSC Exo           | Intravenous injection                               | II and III |
| Enrolling by invitation | MSC Exo inhalation in COVID-19 associated pneumonia                  | SARS-CoV-2 pneumonia                                                       | MSC Exo                      | Inhalation of 0.5–2 x 10¹⁰ nanoparticles           | II    |
| Completed              | MSC Exo inhalation in COVID-19 associated pneumonia                  | SARS-CoV-2 pneumonia                                                       | MSC Exo                      | Inhalation of 0.5–2 x 10¹⁰ nanoparticles           | I and II |
| Not yet recruiting     | MSC Exo for dystrophic epidermolysis bullosa                         | Dystrophic epidermolysis bullosa                                           | Allogenic bone marrow MSC Exo | Topical administration                              | I and II |
| Completed              | MSC EVs inhalation in COVID-19 associated pneumonia                  | Covid19                                                                   | Bone marrow MSC Exo          | Intravenous                                        | II     |
| Not yet recruiting     | MSC CM on enhancers of bone formation in bone grafting              | Bone loss, osteoclastic                                                   | Autologous adipose MSC CM    | Injection to the maxillary sinuses                  | I     |

Exo, exosomes; CM, condition media; MSC, mesenchymal stem cells; ND, none determined; EVs, extracellular vesicles
Table 2  Currently available methods for the isolation and purification of Exo

| Method                     | Advantage                                                                 | Disadvantage                                                                 |
|----------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Sequential ultracentrifugation | Low cost/contamination rate, approximate for large-volume samples         | Time-consuming, Damage to exosomal integrity, genomic and proteomic aggregation, expensive equipment, the existence of other extracellular vesicles |
| Gradient ultracentrifugation | High-rate Exo purity, fractioning of extracellular vesicles into different subsets, large-volume samples | Time-consuming, mechanical damage to exosomal integrity, expensive equipment |
| Size exclusion chromatography | High-rate purification of Exo, suitable for Exo isolation without any damages, Fast and precise | Expensive equipment, the multi-step isolation procedure                         |
| Ultrafiltration             | Fast and precise, relatively low cost                                    | Damage to Exo, loss of Exo in samples, low to moderate purity                  |
| Polymer precipitation       | High-rate purity, applicable for both small- and large-sized samples      | Polymer contamination, protein aggregation, multi-step preparation, time-consuming |
| Immunoaffinity             | Applicable for isolation of distinct Exo subpopulation, High-rate purity, Easy to use | Expensive, applicable for low-sized samples, the possibility of Exo damage, low-content Exo yield |
| Microfluidics               | High-rate Exo purity, cost-effective                                     | Applicable for low-sized samples                                              |

Fig. 2  The injection of Exo may lead to allo-/xeno-reactive T cell responses via the activity of APCs located inside the hepatic and splenic tissues. In addition, systemically injected Exo can be sequestrated in pulmonary and hepatic vascular beds. Another issue regarding Exo application is the promotion of thrombosis in the vascular niche. Harboring infectious agents via Exo can lead to transmission of these particles into the in vivo milieu.
possibility of infection but also alters the bioactivity of parent cells [28]. As a correlate, parent cells should be carefully monitored for dormant viral infections before application to the in vitro systems for large-scale production of Exo.

The possibility of thrombosis and hemostatic perturbations is the major concerns limiting the extensive application of Exo for therapeutic approaches via systemic route. It seems that the possibility of thrombosis is proportional to Exo concentration. The existence of phosphatidylserine and tissue factor closely correlates with the risk of thrombosis. Notably, large-sized Exo harbor higher pro-thrombotic factors compared to small-sized counterparts [29]. Therefore, one can hypothesize that Exo isolated from biofluids have higher thrombosis risk because of tissue factor and other procoagulant factors when compared to Exo are purified from parent cells in in vitro conditions. One reason would be that in systemic circulation Exo are heterogeneous and originated from several cell types mainly platelets and bone marrow megakaryocytes [30, 31]. It was suggested that these cells release Exo which are CD41 and high-mobility group box 1, promoting the possibility of vascular injury and thrombosis (Fig. 2) [32]. Therefore, it is mandatory to select appropriate sources for Exo purification according to therapeutic purposes. Contrary to common belief, allogenic Exo can be uptaken by APCs, leading to allo-reactive T cell responses [33]. Whether the intensity and duration of allo-reactive T cell response are more compared to whole-cell transplantation needs further investigation.

Regarding trivial levels of recognition elements such as MHC-1 on the Exo surface and rapid cell entry event, it is logical to hypothesize that the exposure time of T lymphocytes and APCs with allo-reactive Exo is too short compared to transplant allogeneic MSCs (Fig. 2) [34, 35]. Although the existence of immune modulatory cytokines such as transforming growth factor-beta and interleukin-10 has been previously indicated in MSC-derived Exo, it should not be overlooked that repeated dosing of allogenic and especially xenogeneic Exo increases the likelihood of allo-/xeno-reactive responses [10]. Systemically administrated Exo can be eliminated via the activity of hepatic and splenic macrophages and pulmonary endothelial cells [35]. This phenomenon would result in the activation of APCs and failure to reach the proper dose of Exo into the target sites. Deciphering the underlying molecular pathways that lead to T cell and APC activation post-Exo administration is the subject of area.

Conclusions
Progress in our knowledge about Exo has led to the understanding of their therapeutic properties and making them superior over their counterpart MSCs. Apart from differentiation capacity, MSCs exhibit noteworthy activity to secret soluble factors via Exo, accelerating the regeneration procedure possibly more than when committing to the functional mature cell types [36]. Understanding several aspects related to Exo properties have paved a way for efficient therapeutic strategies. Regarding their physicochemical properties, Exo have opened novel hopeful avenues for the alleviation of several pathologies. It is suggested that Exo can efficiently alter target singling molecules in the recipient cells, making them an appropriate therapeutic modulator in regenerative medicine.

Of note, the possibility of undesirable side effects is less, if not completely, compared to whole-cell transplantation (Table 3). Unique stability and size of Exo increase in vivo biodistribution rate with a low probability of aggregation after systemic injection. Moreover, the efficiency of delivery into the recipient cells can be selectively increased using surface and content modification strategies [37]. Despite these advantages, the lack of GMP-grade preparation protocols and definitions are major hurdles in the field of Exo therapy. It seems that critical technological considerations and definition systems are mandatory to

| Challenges                        | Description                                                                 |
|-----------------------------------|-----------------------------------------------------------------------------|
| Isolation and purification methods| Lack of standard protocol for Exo isolation, leading to heterogeneity in Exo quality and quantity |
|                                    | Impurity and contamination with non-Exo components                           |
|                                    | The possibility of Exo damage                                                |
| Biosafety                          | Contamination of Exo samples with infectious agents during isolation from biofluids or in vitro systems |
| Storage and maintenance            | Temperature- and pH-dependent changes in Exo profile and physicochemical properties |
| In vivo administration             | Possibility of thrombosis and biodistribution to nontarget organs           |
|                                    | Allo-reactive responses and elimination of Exo by the reticuloendothelial system |
| In vitro culture system condition  | Effect of culture medium components on Exo production and cargo profile     |
|                                    | Contamination of Exo samples with exogenous Exo, protein and other biomolecules |

Table 3 Possible challenges related to Exo application in regenerative medicine
obtain a better safety profile after Exo administration inside the in vitro conditions.

Abbreviations
APCs: Antigen-presenting cells; ECM: Extracellular matrix; Exo: Exosomes; FBS: Fetal bovine serum; GMP: Good manufacturing practices; HSP70: Heat shock protein 70; HIV-1: Human immunodeficiency virus-type 1; HTLV-1: Human T-cell leukemia virus-1; MHC-I: Major histocompatibility complex I; MSCs: Mesenchymal stem cells.

Acknowledgements
Not applicable.

Authors’ contributions
AR and RR collected and interpreted data. RR supervised the study. All authors read and approved the final manuscript.

Funding
Funding was provided by Tabriz University of Medical Sciences (No. IR.TBZMED.VCR.REC.1397.395) and National Institute for Medical Research Development (No. IR.NIMAD.REC.1397.512).

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 2 Koç University Research Center for Translational Medicine (KUFTAM), Rumeli Feneri, 34450 Sarıyer, Istanbul, Turkey. 3 Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 4 Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Daneshgah St, Tabriz 5166634311, Iran.

Received: 19 August 2021 Accepted: 17 September 2021 Published online: 28 September 2021

References
1. Rahbarghazi R, Nassiri SM, Khazrainia P, Khalajzadeh A-M, Ahmadi SH, Mohammad E, Molazem M, Zamani-Ahmadmahmoudi M. Juxtaclinc and paracrine interactions of rat marrow-derived mesenchymal stem cells, muscle-derived satellite cells, and neonatal cardiomyocytes with endothelial cells in angiogenesis dynamics. Stem Cells Dev. 2013;22(6):855–65. https://doi.org/10.1089/scd.2012.0377.
2. Mirshoohi F; Ahmadi M, Rezabakhsh A, Rajabi H, Rahbarghazi R, Keyhanmanesh R. Unraveling the therapeutic effects of mesenchymal stem cells in asthma. Stem Cell Res Ther. 2020;11(1):400. https://doi.org/10.1186/s13287-020-01921-2.
3. Yang Y-HK, Ogando CR, Wang See C, Chang T-Y, Barabino GA. Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. Stem Cell Res Ther. 2018;9(1):131–131. https://doi.org/10.1186/s13287-018-0876-3.
4. Mitrousis N, Fokina A, Shoichet MS. Biomaterials for cell transplantation. Nat Rev Mater. 2018;3(11):441–56.
5. Amini H, Rezabakhsh A, Heidarzadeh M, Hassanpour M, Hashemzadeh S, Ghaderi S, Sokullu E, Rahbarghazi R, Reiter RJ. An examination of the putative role of melatonin in exosome biogenesis. Front Cell Dev Biol. 2021;9:1396. https://doi.org/10.3389/fcell.2021.686655.
6. Tang Y, Zhou Y, Li H-J. Advances in mesenchymal stem cell exosomes: a review. Stem Cell Res Ther. 2021;12(1):71. https://doi.org/10.1186/s13287-021-02138-7.
7. Angulski AB, Capignigle LG, Batista M, Marcon BH, Senegaglia AG, Stirmamiglio MA, Correa A. The protein content of extracellular vesicles derived from expanded human umbilical cord blood-derived CD133+ and human bone marrow-derived mesenchymal stem cells partially explains why both sources are advantageous for regenerative medicine. Stem Cell Rev Rep. 2017;13(2):244–57.
8. Bagheri HS, Mousavi M, Rezabakhsh A, Rezaie J, Rasta SH, Nouraziarain A, Avci CB, Tajalli H, Talebi M, Orayan A. Low-level laser irradiation at a high power intensity increased human endothelial cell exosome secretion via Wnt signaling. Lasers Med Sci. 2018;33(5):1131–45.
9. Moghadas S, Bervy M, Rahman HS, Sukstans W, Jallil AT, Abdelbasset WK, Yumashev AV, Shariatzadeh S, Motavalli R, Behzad F, Marofi F, Hassanzadeh A, Pathak Y, Jarahian M. A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine. J Transl Med. 2019;17(1):302. https://doi.org/10.1186/s12967-021-02980-6.
10. Dabrowski S, Andrezjewska A, Janowski M, Lukomska B. Immunomodulatory and regenerative effects of mesenchymal stem cells and extracellular vesicles: therapeutic outlook for inflammatory and degenerative diseases. Front Immunol. 2021;11:3809. https://doi.org/10.3389/fimmu.2020.591065.
11. Marbán E. The secret life of exosomes: what bees can teach us about next-generation therapeutics. J Am Coll Cardiol. 2018;71(2):193–200. https://doi.org/10.1016/j.jacc.2017.11.013.
12. Jabbari N, Akbariazar E, Febghi M, Rahbarghazi R, Rezaie J. Breast cancer-derived exosomes: tumor progression and therapeutic agents. J Cell Physiol. 2020;235(10):6345–56. https://doi.org/10.1002/jcp.29668.
13. Li X, Corbett AL, Taatizadeh E, Tasnim N, Little JP, Garnis C, Daugaard M, Guns E, Hoorfar M, Li ITS. Challenges and opportunities in exosome research—perspectives from biology, engineering, and cancer therapy. APL Bioeng. 2019;3(11):11503-011503. https://doi.org/10.1063/1.5107822.
14. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;204(4):373–83. https://doi.org/10.1083/jcb.2012111013.
15. Yang D, Zhang W, Zhang H, Zhang F, Chen L, Ma L, Larcher LM, Chen S, Liu N, Zhao Q. Progress, opportunity, and perspective on exosome isolation-efforts for efficient exosome-based theranostics. Theranostics. 2020;10(8):3684.
16. Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in exosome isolation techniques. Theranostics. 2017;7(3):789.
17. Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandemompele J, Bracke M, De Wever O, Hendrix A. The impact of disparate isolation-efforts for efficient exosome-based theranostics. Theranostics. 2020;10(8):3684.
18. Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in exosome isolation techniques. Theranostics. 2017;7(3):789.
19. Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandemompele J, Bracke M, De Wever O, Hendrix A. The impact of disparate isolation-efforts for efficient exosome-based theranostics. Theranostics. 2020;10(8):3684.
20. Lee M, Ban J-J, Im W, Kim M. Influence of storage condition on exosome recovery. Biotechnol Bioprocess Eng. 2016;21(2):299–304.
21. Pedrioli G, Piovesana E, Vecchi E, Babici C. Extracellular vesicles as promising carriers in drug delivery: considerations from a cell biologist’s perspective. Biology. 2021;10(5):376.
22. Cheng Y, Zeng Q, Han Q, Xia W. Effect of pH, temperature and freezing-thawing on quantity changes and cellular uptake of exosomes. Protein Cell. 2019;10(4):295–9. https://doi.org/10.1007/s13238-018-0529-4.
23. Wiest EF, Zubair AC. Challenges of manufacturing mesenchymal stromal cell-derived extracellular vesicles in regenerative medicine. Cytotherapy. 2020;22(11):606–12.
24. Patel DB, Gray KM, Santharam Y, Lamichhane TN, Stroka KM, Jay SM. Impact of cell culture parameters on production and vascularization bioactivity of mesenchymal stem cell-derived extracellular vesicles. Bioeng Transl Med. 2017;2(2):170–9.

25. Ludwig N, Whiteside TL, Reichert TE. Challenges in exosome isolation and analysis in health and disease. Int J Mol Sci. 2019;20(19):4684. https://doi.org/10.3390/ijms20194684.

26. Burger D, Turner M, Xiao F, Munkonda MN, Akbari S, Burns KD. High glucose increases the formation and pro-oxidative activity of endothelial microparticles. Diabetologia. 2017;60(9):1791–800.

27. Liu Y, Defourny KA, Smid EJ, Abee T. Gram-positive bacterial extracellular vesicles and their impact on health and disease. Front Microbiol. 2018;9:1502.

28. Rezaie J, Aslan C, Ahmadi M, Zolbanin NM, Kashanchi F, Jafari R. The versatile role of exosomes in human retroviral infections: from immunopathogenesis to clinical application. Cell Biosci. 2021;11(1):19. https://doi.org/10.1186/s13578-021-00537-0.

29. Silachev DN, Goryunov KV, Shpilyuk MA, Beznoschenko OS, Morozova NY, Kraevaya EE, Popkov VA, Pevzner IB, Evtushenko EA. Effect of MSCs and MSC-derived extracellular vesicles on human blood coagulation. Cells. 2019;8(3):258.

30. Kumar SR, Kimchi ET, Manjunath Y, Gajagowii S, Stuckel AJ, Kaifi JT. RNA cargos in extracellular vesicles derived from blood serum in pancreas-associated conditions. Sci Rep. 2020;10(1):2800. https://doi.org/10.1038/s41598-020-05923-0.

31. Kerriis EW, Hopcat C, Calderon T, Freishtat RJ. Platelets and platelet extracellular vesicles in hemostasis and sepsis. J Invest Med. 2020;68(4):813–20.

32. Chen Y, Li G, Liu Y, Werth VP, Williams KJ, Liu ML. Translocation of endogenous danger signal HMGB1 from nucleus to membrane microvesicles in macrophages. J Cell Physiol. 2016;231(11):2319–26.

33. Pruneville A, Babker-Mohamed MH, Aslami C, Gonzalez-Nolasco B, Mooney N, Benichou G. T cell antigenicity and immunogenicity of allogeneic exosomes. Am J Transplant. 2021;21(7):2583–9. https://doi.org/10.1111/ajt.16691.

34. Cai XX, Zhu R, Ran L, Li YQ, Huang K, Peng J, He W, Zhou CL, Wang RP. A novel non-contact communication between human keratinocytes and T cells: exosomes derived from keratinocytes support superantigen-induced proliferation of resting T cells. Mol Med Rep. 2017;16(5):7032–8. https://doi.org/10.3892/mmr.2017.7492.

35. Imai T, Takahashi Y, Nishikawa M, Kato K, Morishita M, Yamashita T, Matsumoto A, Charoenviyakul C, Takakura Y. Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice. J Extracell Vesicles. 2015;4:26238–26238. https://doi.org/10.3402/jev.v4.26238.

36. Sid-Otmame C, Perrault LP, Ly HQ. Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes. J Transl Med. 2020;18(1):336. https://doi.org/10.1186/s12967-020-02504-8.

37. Heidarzadeh M, Gürsoy-Özdemir Y, Kaya M, Abriz AE, Zarebkohan A, Rahbarghaz R, Sokullu E. Exosomal delivery of therapeutic modulators through the blood–brain barrier: promise and pitfalls. Cell Biosci. 2021;11(1):1–28.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.